Control BionicsASX:CBL Net Debt Paydown Yield % is 1.13% as of Jul. 07, 2026, which is 653% above its 10-year median of 0.15. The stock has 4 warning signs investors should review. Among 773 Medical Devices & Instruments companies, Control Bionics ranks better than 72.32% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Control Bionics's Net Debt Paydown Yield % was 1.13%.
Control Bionics (ASX:CBL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Control Bionics Net Debt Paydown Yield % Related Terms
Control Bionics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Control Bionics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Control Bionics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Control Bionics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 1.13% mean?
Control Bionics (ASX:CBL) has a Net Debt Paydown Yield % of 1.13% as of Jul. 07, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Control Bionics and its competitors. This is 653% above median its historical median of 0.15. According to the industry distribution chart, Control Bionics ranks #214 out of 773 companies in the Medical Devices & Instruments industry, placing it in the top 27.7%.
Is Control Bionics' Net Debt Paydown Yield % too high?
Control Bionics' current Net Debt Paydown Yield % of 1.13% is 653% above median its 10-year median of 0.15. The Medical Devices & Instruments industry median Net Debt Paydown Yield % is 0.01. Control Bionics' value of 1.13% is 11200% above this industry median. Based on the distribution chart, Control Bionics ranks #214 out of 773 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' Net Debt Paydown Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #214 out of 773 companies for Net Debt Paydown Yield %. This puts Control Bionics in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.01. Control Bionics' value of 1.13% is 11200% above this benchmark. While the company's 10-year median is 0.15 vs. the industry median of 0.01, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 773 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Net Debt Paydown Yield % of 1.13% is 11200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Net Debt Paydown Yield % is 1.13%, which is 653% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.08 — trading 150% above its estimated fair value. The current Net Debt Paydown Yield % is 1.13%, which is 653% above median its 10-year median of 0.15 and 11200% above the Medical Devices & Instruments industry median of 0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Net Debt Paydown Yield % is 1.13% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 